Supplementary Information for Financial Results Q3 FY12/26
Filed with TSE · · 44 pages · English
Earlier from Chiome Bioscience
- Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30,2026
- Announcement of target-specific research and option agreement with Heidelberg Pharma
- Service agreement with option contract with Rohto Pharmaceutical Co., Ltd.
- First patient in of cancer therapeutic antibody CBA-1535 in a Phase 1 clinical trial
- Conclusion of contract with additional institutes and first dosing of CBA-1205 in the second part of Phase 1 study
Follow Chiome Bioscience into a list and get an email when it puts out news.
Follow Chiome Bioscience